NUC-202
/ Nucorion, Ligand
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
December 30, 2025
Proline-, Glutamic Acid-, Leucine-Rich Protein 1 (PELP1): Diversity, Structural Conservation, and Evolutionary Origins Across the Species.
(PubMed, Int J Mol Sci)
- "Domain analysis revealed that PELP1 proteins contain one RIX1 domain and one or two NUC202 domains...Phylogenetic clustering and sequence identity patterns resolved three major evolutionary lineages corresponding to fungi, filastereans, and metazoans. Overall, these findings reveal that PELP1 proteins exhibit extensive sequence divergence while maintaining a conserved structural architecture, reflecting evolutionary adaptation that preserves functional integrity across opisthokonts."
Journal • PELP1
January 06, 2022
Immunotherapy Approvals Propel the Future of GI Cancer Treatment
(Oncology Nursing News)
- "Finally, your co-chair Anthony El-Khoueiry, MD...discussed shifting treatment strategies for patients with hepatobiliary cancers. How has this field evolved from an area of significant need to one with a crowded armamentarium? What challenges with regard to sequencing have arisen amid recent FDA approvals? We've seen huge changes in hepatobiliary cancer. We have several positive trials now in the frontline setting combining immunotherapy with VEGF inhibitors, both using agents such as bevacizumab [Avastin] and TKIs."
Media quote
February 10, 2021
2020 ASCO Highlights Denver | Gastrointestinal Cancers - Non Colorectal
(YouTube)
- "From our 2020 ASCO Direct Highlights Denver Conference, we bring you a session on non-colorectal cancer by Dr. Caio Max Sao Pedro Rocha Lima. He discusses, gemcitabine, nabpaclitaxel, Folfirinox, and more."
Video
1 to 3
Of
3
Go to page
1